BrainEver and 3P Biopharmaceuticals Collaborate on Development of Recombinant Human Homeoprotein Engrailed-1
Noáin, Spain, November 15, 2022: 3P Biopharmaceuticals (3P), a
leading contract development and manufacturing organization (CDMO)
specializing in the process development and cGMP manufacturing of
biological products and BrainEver a French biotechnology company
focusing on discovering and developing First-in-Class therapies for the
treatment of neurodegenerative diseases have entered into a long term
collaboration to develop hEng1 a recombinant homeoprotein to treat
pathologies such as Amyotrophic Lateral Sclerosis (ALS) or Parkinson's
disease.
More info >> |